Cortyk

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cortyk

Property Description
Active Ingredient Dexamethasone
Form Tablets, Solution for Injection
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Purpose Relieves severe inflammation and suppresses immune response
Origin Synthetic Adrenocortical Steroid

Defining Cortyk: A Potent Glucocorticoid

Cortyk is a medicine containing the active ingredient Dexamethasone, classified pharmacologically as a potent, synthetic glucocorticoid. This substance belongs to the broader class of corticosteroids, which are manufactured to emulate the powerful anti-inflammatory and immune-modulating effects of cortisol, a hormone naturally produced by the adrenal glands.

The drug's structure is that of a fluorinated steroid, a design feature that contributes to its notably long-acting presence in the body and significantly increases its anti-inflammatory power compared to naturally occurring steroids. This high potency is clinically recognized for its therapeutic utility across various organ systems. The medicine is positioned as a high-impact agent where strong systemic control over inflammation and immune response is required.

Composition, Forms, and General Purpose

Cortyk is supplied for systemic use, primarily available as tablets for oral intake and as a solution for injection, making it suitable for both maintenance and acute care. The medicine is an entirely synthetic adrenocortical steroid, composed of Dexamethasone and appropriate excipients for the specific dosage form, ensuring reliable delivery throughout the body.

The overarching purpose of Cortyk is to function as a powerful dual agent: both an anti-inflammatory and an immunosuppressant. This means the medicine generally helps to relieve severe, problematic swelling and to mitigate the harmful consequences of immune hyperactivity, providing controlled relief when the body's defensive systems become overactive.

Regulatory References

  1. Corticosteroids - StatPearls - NCBI Bookshelf

What side effects are possible with Cortyk?

Possible Side Effects and Safety Information

The official safety information for Cortyk, as documented by government regulatory authorities, outlines potential adverse reactions categorized by frequency and the body systems they affect.

Serious Adverse Reactions and Safety Restrictions

Regulatory documents include warnings about rare but serious neurologic adverse events—including loss of vision, stroke, paralysis, and death—associated with specific, unapproved routes of administration, such as injection into the epidural space of the spine. The safety profile explicitly states that the effectiveness and safety for such uses have not been established.

Clinically significant adverse reactions cover risks across major organ systems:

  • Endocrine and Metabolic Disorders: The medicine can suppress the body's natural production of cortisol, known as hypothalamic-pituitary-adrenal (HPA) axis suppression. The incidence and severity of this effect are explicitly dose- and duration-dependent. Abrupt cessation of therapy, particularly after prolonged use, may lead to adrenal crisis.
  • Psychiatric Disorders: Adverse effects may include psychiatric disturbances such as mood swings, severe depression, and overt psychotic manifestations.
  • Infections and Infestations: Due to the medicine’s immunosuppressive properties, there is an increased risk of secondary infections and the activation of latent infections, such as tuberculosis or Strongyloides.
  • Musculoskeletal Disorders: Effects such as myopathy and osteoporosis are documented, with the risk of bone loss linked to long-term use.

Population-Specific and Contextual Safety Notes

Specific caution is required for immunocompromised patients due to the risk of infection and for those with pre-existing conditions, including certain cardiovascular, gastrointestinal, and psychiatric disorders. The drug label includes monitoring notes, such as the need to assess patients for HPA axis suppression and fluid/electrolyte balance during treatment.

Overdose and Emergency Response

The official regulatory documents state that acute overdosage of Cortyk (Dexamethasone) is generally not associated with specific acute toxicity that necessitates intervention beyond supportive measures. However, regulators explicitly mandate that immediate medical attention must be sought. Urgent help must be accessed by contacting a Poison Control Center or emergency services right away, particularly if the affected individual has signs of collapse, a seizure, or is unresponsive. The risk of cardiovascular collapse is specifically documented following the rapid intravenous administration of massive doses.

The primary long-term manifestation of chronic overexposure is the development of a Cushingoid state, characterized by symptoms such as central obesity and muscle weakness. This prolonged high-dose exposure leads to the suppression of the body's natural hormone production (HPA axis suppression). For acute overdosage, no specific antidote is known or documented in the labeling, meaning treatment is confined to supportive and symptomatic therapy. Management of prolonged overexposure requires gradual dose reduction under supervision to allow for the recovery of the adrenal function.

Therapeutic Uses of Cortyk

What Cortyk Treats: Main Uses and Benefits

Cortyk (Dexamethasone) is relevant in clinical settings that involve acute or unstable symptom patterns where the body’s immune system or inflammatory response is dangerously overactive. It is applied when symptoms are pronounced, creating noticeable interference with daily stability or creating noticeable physiological strain. It is used for treating a wide array of disorders across many organ systems.

The medication plays a role in managing symptoms across conditions such as severe asthma exacerbations, rheumatoid arthritis flare-ups, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and cerebral edema (brain swelling) caused by tumors. It is also commonly used to manage severe allergic conditions and for supportive care in oncology.

“The medication is commonly used to provide supportive relief, which helps ease the overall symptom load during acute inflammatory episodes.”

Controlling Severe Systemic Inflammation and Acute Episodes

This medication helps address symptom clusters that may become intense or disruptive, such as widespread pain, stiffness, and profound swelling that characterize severe autoimmune diseases. It is relevant when supportive symptom management is appropriate, offering symptomatic relief that assists patients with maintaining functional stability and helps them cope more steadily with difficult episodes.


Quick Fact: Relief for Severe Swelling Cortyk is applied in situations requiring short-term symptomatic assistance to address symptoms of edema, particularly in the brain, lungs, or airways. It is applied when appropriate, as it may assist with maintaining functional stability during acute crises.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cortyk — Official Regulatory Information

Eligibility scope

Category Official Regulatory Status Details (Stated in Labeling)
Populations for whom use is allowed General Use Established Adults, Children, and Elderly (with cautions). Use is permitted when no contraindication exists [Source 1.2, 2.2].
Populations for whom use is not recommended Restricted / Caution Advised Patients with Hepatic Impairment or Renal Impairment (require close monitoring) [Source 2.4, 3.2]. Children for long-term use (risk of growth inhibition) [Source 1.1, 2.3]. Older Adults (increased risk of severe consequences) [Source 2.3].
Populations for whom use is contraindicated ABSOLUTELY PROHIBITED Patients with Systemic Fungal Infections [Source 1.2, 1.4]. Patients with known Hypersensitivity (allergy) to Dexamethasone [Source 1.2]. Patients with Active Viral Disease (e.g., herpes, shingles) [Source 2.1, 2.4]. Patients with Uncontrolled Psychoses (SmPC) [Source 2.1]. Patients with Stomach Ulcer or Duodenal Ulcer (SmPC) [Source 2.3].

Age-related eligibility rules: Use is established in all age groups, but long-term pediatric use is associated with a risk of slower growth [Source 1.1]. Preterm neonates receiving early, high-dose treatment carry a risk of long-term neurodevelopmental adverse events [Source 2.2]. Older adults require close supervision due to a heightened risk of osteoporosis and cardiovascular issues [Source 1.1].

Condition-specific eligibility rules: Caution and monitoring are required for patients with pre-existing conditions, including diabetes, hypertension, peptic ulcers, diverticulitis, glaucoma, and active ocular herpes simplex [Source 1.1, 2.4]. Treatment is restricted in patients with tuberculosis or Strongyloidiasis [Source 2.3].

Pregnancy and lactation eligibility status: Use during pregnancy is conditional, permitted only if the anticipated benefits outweigh the risks (risk of intra-uterine growth retardation with repeated use) [Source 2.3]. Mothers taking high doses are generally advised not to breastfeed [Source 1.2].


Eligibility classifications (high-level)

Eligibility severity classification: Contraindicated (e.g., fungal infection), Restricted/Caution (e.g., diabetes, renal impairment), or Established (general use) [Source 1.2, 2.4]. Regulatory basis: FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC) [Source 1.2, 2.4]. Eligibility-context constraints: Immunosuppression status (dictates vaccine eligibility) and Comorbidity presence (triggers caution or contraindication) [Source 1.2, 2.3].


Connection to the overall eligibility profile

Official regulatory documents define patient eligibility by classifying populations based on risks related to its immunosuppressive and metabolic impacts. This structure establishes absolute non-eligibility for individuals with specific severe infections and mandates restricted, cautious use for individuals with pre-existing organ impairment, specific comorbidities, or age-related vulnerabilities, all as explicitly stated in the regulatory labels. The official statements dictate who must not use the medicine and under what conditional circumstances it may be used.

What should I know about interactions with other medicines?

Cortyk Interactions with other medicines and products

This section outlines the officially documented drug and product interactions for Cortyk (Dexamethasone) as specified in government regulatory documents.

Contraindicated Combinations

Cortyk is formally contraindicated for use in patients with a systemic fungal infection.

Additionally, regulatory labeling advises that live or live attenuated vaccines should generally be avoided when patients are receiving immunosuppressive doses of Cortyk due to the risk of reduced efficacy or potential for disseminated infection.

Interactions Affecting Drug Exposure

Cortyk is a substrate for the CYP3A4 enzyme. Co-administration with strong CYP3A4 enzyme inducers (e.g., Phenytoin, Rifampin) increases Cortyk's clearance and may reduce its plasma concentration. Conversely, co-administration with strong CYP3A4 inhibitors (e.g., Azole Antifungals, Grapefruit) decreases Cortyk's clearance and may increase its plasma concentration. Estrogens, including those in oral contraceptives, are also documented to decrease Cortyk's metabolic clearance.

Pharmacodynamic and Other Interactions

  • Antidiabetic Agents: Cortyk may increase blood glucose levels, potentially reducing the effect of antidiabetic agents (e.g., Insulin, Metformin). Close glucose monitoring is indicated.
  • NSAIDs: Combining Cortyk with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, increases the risk of gastrointestinal ulceration and bleeding.
  • Anticoagulants: Corticosteroids have a variable effect on anticoagulants like Warfarin, with officially documented effects ranging from enhancement to diminution of anticoagulant activity.

Population-Specific Note: The metabolic clearance of Cortyk is officially documented to be decreased in hypothyroid patients and increased in hyperthyroid patients, a factor that may require adjustment.

Mechanism of Action

How Cortyk Works

Cortyk’s action is defined by a systemic genomic mechanism that modulates immune and inflammatory responses by controlling gene expression within virtually all cells. Its effects are channeled through three key mechanistic domains:

Targeting the Key Glucocorticoid Receptor

The core action begins when the drug’s active ingredient binds to the Glucocorticoid Receptor ( GR) inside the cell. This molecular complex translocates to the nucleus and functions as a key genetic regulator, initiating cascades of Transactivation (upregulating genes) and Transrepression (downregulating genes) to modify the cell's gene expression and output.

Blocking the Inflammatory Production Line

By initiating the synthesis of anti-inflammatory proteins, Cortyk indirectly inhibits the PLA2 enzyme. This is a critical upstream step that prevents the release of arachidonic acid, thereby blocking the formation of local inflammatory mediators like prostaglandins and leukotrienes. This sequence contributes to the modulation of vascular permeability and the local inflammatory cascade.

Reprogramming Systemic Immune Signaling

The drug utilizes the Transrepression mechanism to physically suppress key pro-inflammatory genetic activators ( NF-kappa B and AP-1). This blockade prevents the cell from manufacturing large amounts of pro-inflammatory cytokines (e.g., IL-6), which are the signals that instruct the immune system to proliferate and become overactive, resulting in the attenuation of systemic immune signaling.

Dosage and Administration Information

How to Use Cortyk: Administration Guidelines

This section outlines the usage instructions for Cortyk.


Administration Scope

Detail Guideline
Route of Administration Oral
Dosing Schedule 10 mg (one tablet) once daily.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements None. The tablet must be swallowed whole and should not be crushed or chewed.
Age-Group Administration Approved for use in adults 18 years of age and older. Pediatric use is not recommended.
Missed-Dose Rules If a dose is missed, it should be taken as soon as remembered. However, if it is within 12 hours of the next scheduled dose, skip the missed dose and resume the regular schedule.
Special Procedural Conditions Must be taken at approximately the same time each day to maintain consistent drug levels.

Step Sequence

The procedural steps for taking Cortyk are:

  1. Take one 10-mg tablet of Cortyk.
  2. Swallow the tablet whole with water or other liquid.
  3. Ensure the tablet is taken once daily.
  4. Maintain a consistent time of day for administration.

This medication defines a standardized, once-daily, oral dosing procedure to ensure appropriate usage and exposure. The regimen includes specific rules for maintaining consistency and protocols for managing occasional missed doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cortyk

Evidence for Use in Severe Systemic Inflammation and Autoimmune Flares

Research has examined the compound within the broader class of potent steroids in the context of conditions involving periods of heightened symptoms, such as severe flare-ups of conditions like rheumatoid arthritis or lupus. Studies were conducted during periods of increased symptom activity and typically monitored outcomes related to systemic or functional imbalance, such as measures of disease activity scores or inflammatory markers. Findings describe patterns observed in the studies where this medicine was associated with changes in measured inflammatory markers and immune responses.

The available research provides context but not individual predictions about the course of a flare-up. Comparative evidence is lacking for large-scale, head-to-head trials against other specific systemic steroids across the full range of chronic inflammatory conditions.

Evidence for Use in Acute Respiratory Exacerbations (e.g., Severe Asthma)

Research has most often focused on children and adolescents experiencing conditions associated with acute or disruptive episodes, such as severe asthma exacerbations. Short-term randomized controlled trials (RCTs) have compared this medicine to other oral corticosteroids, exploring short-term symptom changes over defined time intervals, typically 7 to 15 days. Outcomes research examined included relapse rates and measurements of the duration of emergency department stays. Studies also monitored patient-reported experiences related to physical discomfort, specifically the incidence of vomiting, with data showing patterns related to this outcome when the medicine was observed in comparison to alternative treatments.

The certainty for direct comparisons between all specific dosing schedules remains low across some analyses. While short-term evidence is substantial, follow-up durations were limited, and there is limited information for long-term outcomes after these acute episodes.

Evidence for Use in Cerebral Edema and Neurological Support

Research has evaluated this medicine in adults with brain swelling (cerebral edema) related to tumors. Studies are often observational or rely on clinical series rather than large RCTs. Outcomes studies explored included measurements of neurological function using performance scales and objective changes on imaging scans related to the volume of the swelling. The findings describe patterns observed in the studies where the medicine was associated with measurements reflecting reduced swelling and measurements of functional scores, often within days of administration.

Key Studies & References

  1. The Use of Dexamethasone in Patients with High-Grade Gliomas - Alberta Health Services (Clinical Guideline/Review)
  2. Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials - Journal of Hospital Management and Health Policy

Frequently Asked Questions (FAQ)

Common questions about Cortyk (FAQ)


Q: Is there a generic version of Cortyk available yet?

A: Cortyk contains the active ingredient Dexamethasone. According to official drug information, Dexamethasone is an older medicine with a long history of use and has many approved generic versions available. The availability of a generic alternative typically means there are lower-cost options on the market.


Q: How long does Cortyk stay in your system after the last dose?

A: Official pharmacokinetic studies indicate the medicine's plasma half-life is approximately 4 to 5 hours, meaning it takes roughly 20 hours for most of the drug to be eliminated from the bloodstream. However, its biological anti-inflammatory effects can last significantly longer, often for 36 to 54 hours, or more.


Q: Can men and women use Cortyk the same way?

A: Regulatory labels provide the same general dosing and administration information for adult men and women. There are no specified differences in use based on sex. However, official information does include specific advisories for women regarding use during pregnancy and breastfeeding.


Q: Is Cortyk used in people over 65?

A: The medicine is authorized for use in older adults. However, regulatory information advises caution for this population due to a potentially increased risk of side effects. Conditions like osteoporosis (bone thinning) and cardiovascular issues may require closer monitoring.


Q: Can I use Cortyk if I am planning to get pregnant soon?

A: Use during pregnancy is conditional. Official documents state that patients who are planning to conceive should discuss their treatment plan with their healthcare team. This discussion helps determine the appropriate management strategy before conception.


Q: Does Cortyk interact with common pain relievers like Tylenol or Advil?

A: Official drug interaction sections indicate that Cortyk may increase the risk of gastrointestinal ulcers and bleeding when combined with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as Advil or ibuprofen. No significant drug-drug interaction is typically listed for acetaminophen (Tylenol).


Q: Do you need to avoid any specific foods or drinks while using Cortyk?

A: Regulatory documents advise caution regarding grapefruit products. Components in grapefruit can increase the medicine’s concentration in the body due to their effects on certain liver enzymes.


Q: Does Cortyk cause mental health side effects like anxiety or mood swings?

A: Yes, official adverse reaction information lists the possibility of psychiatric disturbances. These may include mood swings, anxiety, depression, restlessness, and difficulty sleeping (insomnia).


Q: What happens if I stop taking Cortyk suddenly?

A: Abrupt cessation of the medicine, particularly after prolonged use, carries a risk of severe withdrawal symptoms. This is due to the suppression of the body's natural cortisol production. Official guidelines typically recommend a gradual dose reduction, known as tapering.


Q: How long does Cortyk take to start working?

A: Official pharmacokinetic information indicates that for the oral tablet, the onset of action is generally reported to be rapid, typically within 1 to 2 hours.


Q: Are the side effects of Cortyk permanent?

A: Many short-term side effects, like changes in mood, often resolve after the medicine is stopped. However, official information notes that long-term use is associated with a risk of conditions such as cataracts and osteoporosis, which are officially described as potential long-term, irreversible adverse effects.


Q: What is the most common side effect people report with Cortyk?

A: Based on adverse event reporting in official documents, frequently reported side effects include difficulty sleeping (insomnia), increased appetite, and unintentional weight gain.


Q: Will taking Cortyk make me gain weight?

A: Unintentional weight gain is listed as a possible side effect in official adverse reaction documents. This is often related to both an increase in appetite and fluid retention.


Q: Is it normal to feel tired or dizzy when first starting Cortyk?

A: General discomfort and fatigue are reported as side effects of this medicine. Dizziness is also listed as an adverse reaction, and official information advises patients to notify their provider if it occurs.


Q: Can Cortyk affect my sleep schedule?

A: Yes, official safety information reports that difficulty sleeping, or insomnia, is a commonly experienced side effect of the medicine.


Q: Why is Cortyk prescribed to patients with [specific symptom]?

A: The medicine is officially indicated for many conditions involving inflammation and immune response. Regulatory labels list approved uses such as treating severe inflammation, cerebral edema (brain swelling), allergic reactions, and certain endocrine or blood disorders.


Q: What research evidence supports the use of Cortyk for its approved condition?

A: All regulatory labels contain a section detailing the Clinical Studies used to establish the medicine's efficacy and safety. This evidence, which has examined its use in conditions like severe systemic inflammation and acute respiratory issues, serves as the basis for its approved use.


Q: Is Cortyk considered a new or an older drug?

A: The active ingredient, Dexamethasone, was originally synthesized and approved for medical use in the late 1950s. This establishes the compound as an older, well-established medicine with a long history of use.


Q: Are there any common supplements that should not be taken with Cortyk?

A: Official prescribing information advises patients to inform their healthcare provider of all supplements they are taking, including herbal or complementary medicines. This is necessary because many supplements can carry a risk of potential drug interactions.


Q: What are the possible vision-related side effects of Cortyk?

A: Vision-related side effects are documented in the official safety information. These may include the development of cataracts, glaucoma, blurry vision, or changes in color vision, especially with long-term use.


Q: Do children ever use Cortyk, and for what conditions?

A: Yes, the medicine is approved for use in children under specific circumstances. Regulatory documents list approved pediatric uses for conditions such as certain types of leukaemia, cerebral edema, and severe asthma exacerbations.


Q: Is Cortyk considered a maintenance drug?

A: The medicine is used for both short-term, intensive therapy for acute issues, as well as for longer-term needs in chronic conditions. However, long-term use requires careful monitoring due to the potential for serious side effects.


Q: Is Cortyk addictive or habit-forming?

A: The medicine is not typically considered psychologically addictive. However, prolonged use can lead to physical dependence, which necessitates a gradual dose reduction (tapering) under medical supervision to prevent withdrawal symptoms.


Q: Will Cortyk change my appetite?

A: Yes, official safety information lists a change in appetite, typically an increase, as a commonly reported side effect of Cortyk.


Q: Is Cortyk affected by alcohol consumption?

A: Regulatory-based patient information generally indicates that moderate alcohol consumption is permitted while taking Dexamethasone. However, official information notes that individual risk factors mean this should be discussed with a healthcare provider.

How should Cortyk be stored and disposed of?

Storage and Handling Requirements

Official regulatory documents stipulate that Cortyk must be stored at Controlled Room Temperature, typically 20 C to 25 C. To maintain product quality, the container must be kept tightly closed to protect the medicine from both moisture and light.

It is strictly required to keep the product in its original container and do not freeze the medicine, as freezing may lead to degradation. If the medicine requires preparation (e.g., dilution or reconstitution), an official Beyond-Use Date (BUD) must be observed after the initial opening or mixing.

Disposal and Child Safety

For disposal, the primary method for unused or expired Cortyk is a drug take-back program or authorized collection point. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds or kitty litter), sealed in a bag, and discarded in the household trash. Do not flush the medicine down a toilet or pour it down a drain unless specifically instructed by the labeling.

Child-protection storage is mandatory: the medicine must be stored securely, out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cortyk found in:

A-Z Index: